NASDAQ:XLO
Xilio Therapeutics, Inc.
- Stock
Last Close
0.96
26/07 20:00
Market Cap
35.44M
Beta: -
Volume Today
88.76K
Avg: 29.09K
PE Ratio
−0.23
PFCF: −0.25
Preview
Full access to financials is available to subscribers only. Please support our work and get full access to all features. You can cancel anytime. If you'd like a demo, free trial or have any questions, please checkout the help page
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | ||
|---|---|---|---|---|---|---|
average inventory | ||||||
average payables | 3.98M - | 4.29M 7.86% | 3.13M 27.00% | 2.09M 33.40% | ||
average receivables | ||||||
book value per share | -1.11 - | -3.12 182.11% | 33.08 1,158.96% | 3.86 88.34% | 1.34 65.27% | |
capex per share | -0.03 - | -0.08 206.01% | -0.20 139.13% | -0.07 65.26% | -0.02 74.07% | |
capex to depreciation | -2.98 - | -2.05 31.04% | -0.73 64.28% | -1.01 37.75% | -0.26 74.70% | |
capex to operating cash flow | 0.04 - | 0.06 51.29% | 0.01 77.53% | 0.02 81.00% | 0.01 71.27% | |
capex to revenue | ||||||
cash per share | 1.83 - | 0.72 60.61% | 35.33 4,796.69% | 4.39 87.56% | 1.63 63.01% | |
days of inventory on hand | ||||||
days payables outstanding | ||||||
days sales outstanding | ||||||
debt to assets | 0.30 - | 0.58 96.68% | 0.09 83.88% | 0.14 52.14% | 0.15 5.27% | |
debt to equity | -0.63 - | -0.25 59.63% | 0.11 143.47% | 0.19 70.42% | 0.25 32.21% | |
dividend yield | ||||||
earnings yield | -0.04 - | -0.13 218.98% | -0.83 540.01% | -1.18 43.03% | ||
enterprise value | 396.44M - | 428.64M 8.12% | -87.82M 120.49% | -26.76M 69.53% | -20.39M 23.80% | |
enterprise value over ebitda | -21.10 - | -8.01 62.03% | 1.17 114.61% | 0.30 74.35% | 0.26 14.16% | |
ev to operating cash flow | -22.22 - | -11.88 46.55% | 1.09 109.16% | 0.35 67.50% | 0.30 15.91% | |
ev to sales | ||||||
free cash flow per share | -0.70 - | -1.44 106.27% | -14.60 917.06% | -2.83 80.60% | -2.51 11.27% | |
free cash flow yield | -0.04 - | -0.09 106.27% | -0.91 917.06% | -1.05 15.40% | -4.57 333.96% | |
graham net net | -1.63 - | -3.76 131.26% | 29.51 883.95% | 3.17 89.25% | 0.75 76.37% | |
graham number | 4.02 - | 12.06 199.98% | 99.31 723.25% | 16.63 83.25% | ||
income quality | 1.03 - | 0.65 36.59% | 1.07 62.99% | 0.86 19.43% | 0.90 4.64% | |
intangibles to total assets | 0 - | 0 | 0 | 0 | 0 | |
interest coverage | 96.17 - | |||||
interest debt per share | 0.70 - | 0.80 13.88% | 3.66 360.38% | 0.69 81.05% | 0.33 51.85% | |
inventory turnover | ||||||
invested capital | -0.63 - | -0.25 59.63% | 0.11 143.47% | 0.19 70.42% | 0.25 32.21% | |
market cap | 426.66M - | 426.66M 0% | 89.70M 78.98% | 73.68M 17.86% | 15.12M 79.48% | |
net current asset value | -41.14M - | -99.01M 140.67% | 169.89M 271.58% | 90.98M 46.45% | 24.03M 73.59% | |
net debt to ebitda | 1.61 - | -0.04 102.30% | 2.37 6,494.63% | 1.13 52.37% | 0.45 60.17% | |
net income per share | -0.65 - | -2.07 218.98% | -13.25 540.01% | -3.19 75.95% | ||
operating cash flow per share | -0.67 - | -1.35 102.27% | -14.40 964.22% | -2.76 80.81% | -2.50 9.72% | |
payables turnover | ||||||
receivables turnover | ||||||
research and ddevelopement to revenue | ||||||
return on tangible assets | -0.28 - | -1.52 450.90% | -0.34 77.59% | -0.63 84.09% | ||
revenue per share | ||||||
roe | 0.59 - | 0.66 13.07% | -0.40 160.44% | -0.83 106.21% | ||
roic | 10.17 - | 1.08 89.40% | -0.34 131.45% | -0.65 91.66% | ||
sales general and administrative to revenue | ||||||
shareholders equity per share | -1.11 - | -3.12 182.11% | 33.08 1,158.96% | 3.86 88.34% | 1.34 65.27% | |
stock based compensation to revenue | ||||||
tangible asset value | -29.52M - | -83.29M 182.11% | 185.43M 322.64% | 105.65M 43.03% | 36.83M 65.14% | |
tangible book value per share | -1.11 - | -3.12 182.11% | 33.08 1,158.96% | 3.86 88.34% | 1.34 65.27% | |
working capital | 45.90M - | -1.56M 103.41% | 189.74M 12,223.90% | 103.38M 45.52% | 32.17M 68.88% |
All numbers in USD (except ratios and percentages)